Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing
Ceftazidime
/ pharmacology
Pseudomonas aeruginosa
/ genetics
Azabicyclo Compounds
/ pharmacology
Microbial Sensitivity Tests
Humans
Drug Combinations
beta-Lactamases
/ genetics
Anti-Bacterial Agents
/ pharmacology
Pseudomonas Infections
/ microbiology
Bacterial Proteins
/ genetics
Drug Resistance, Multiple, Bacterial
/ genetics
Chile
Whole Genome Sequencing
Mutation
PER-3 extended-spectrum β-lactamase
Pseudomonas aeruginosa
blaPER-3 gene
ceftazidime/avibactam resistance
mutations conferring CZA resistance
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2024
2024
Historique:
received:
01
04
2024
accepted:
13
05
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
21
6
2024
Statut:
epublish
Résumé
Ceftazidime/avibactam (CZA) is indicated against multidrug-resistant Antimicrobial susceptibility was determined through agar dilution and broth microdilution, while Twenty-six of 287 isolates studied (9.1%) were CZA-resistant. Thirteen of 26 CZA-resistant isolates (50%) carried PER-3-producing ST309
Identifiants
pubmed: 38903939
doi: 10.3389/fcimb.2024.1410834
pmc: PMC11188487
doi:
Substances chimiques
Ceftazidime
9M416Z9QNR
Azabicyclo Compounds
0
avibactam, ceftazidime drug combination
0
Drug Combinations
0
beta-Lactamases
EC 3.5.2.6
Anti-Bacterial Agents
0
Bacterial Proteins
0
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1410834Informations de copyright
Copyright © 2024 Soto, Alcalde-Rico, Ugalde, Olivares-Pacheco, Quiroz, Brito, Rivas, Munita, García and Wozniak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.